Baxter International, Inc.

Baxter International, Inc.

Baxter International, Inc.

Overview
Date Founded

1931

Headquarters

ONE BAXTER PARKWAY, DEERFIELD, IL, 60015

Type of Company

Public

Employees (Worldwide)

50K

Industries

Medical Products & Equipment
Pharmaceuticals
Wholesale: Medical Supplies & Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2011 sales of $13.9 billion and has approximately 48,500 employees.

Contact Data
Trying to get in touch with decision makers at Baxter International, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Corporate Vice President & President

Executive Vice President & Chief Financial Officer

Senior Vice President & General Counsel

Deputy General Counsel, Global Government Policy & Reimbursement

President, Pharmaceuticals & Senior Vice President, Chief Science & Technology Officer

Chief Information Officer & Senior Vice President

Senior Vice President, Chief Accounting Officer & Controller

General Manager, US Hospital Products

General Manager, US Renal

Board of Directors

President & Chief Executive Officer at Baxter International, Inc.

Former President & Chief Executive Officer at Boston Scientific Corporation

Former Professional at PepsiCo, Inc.

Chairman & Chief Executive Officer at O-I Ltd.

Venture Partner, Menlo Park at New Enterprise Associates

Lead Director at Baxter International, Inc.

Chief Financial & Administrative Officer at Bright Health, Inc.

Co-Founder at Anastasia Marie Laboratories, Inc.

Former Senior Vice President-Strategy at Medtronic Plc

Br Manager at Baxter Healthcare Corporation

Paths to Baxter International, Inc.
Potential Connections via
Relationship Science
You
Baxter International, Inc.
Owners & Shareholders
Details Hidden

MSIM is an active manager which performs bottom-up fundamental research to analyze the industries and companies in which they invest. Research and investment ideas are generated by the London-based Research Cooperative which fosters both intra- and inter-team communications through regular meetings. The firm’s investment strategies span the risk/return spectrum across geographies, investment styles and asset classes, including equity, fixed income, alternatives and private markets. Their portfolio management teams have ultimate responsibility for constructing portfolios.

Details Hidden

Generation Investment Management Generation is an independent, private, owner-managed partnership with offices in London and New York. The firm was co-founded in 2004 by Al Gore and David Blood. Team The Generation team of 55 people represents 16 countries and speaks over 21 languages. Our investment team was founded by bringing together seasoned investment analysts and leaders from the sustainability research field. Today these skills are integrated into Generation's team of 25 investment professionals who have over 150 years of combined investment experience. Sustainable Investing for the Long Term Generation's investment approach is based on the idea that sustainability factors—economic, environmental, social and governance criteria—will drive a company's returns over the long term. By integrating sustainability issues with traditional analysis, we seek to provide superior investment returns.* We are closely aligned with our clients, and our performance is measured over the long term. A Unique Research Platform to Analyze Global Challenges Generation has built a global research platform to integrate sustainability research into fundamental equity analysis. We focus on key drivers of global change, including climate change and environmental degradation; poverty and development; water and natural resource scarcity; pandemics and healthcare; and demographics, migration and urbanization. These global challenges pose risks and opportunities that can materially affect a company's ability to sustain profitability and deliver returns. Our research plays an important role in forming our views on the quality of the business, the quality of management and valuation. A Diverse Advisory Board Our Advisory Board, convened by our Chairman Al Gore, helps set our long term thematic research agenda into global sustainability issues. The Advisory Board is a diverse set of global thinkers who help us anticipate the changing context for business. Vision Generation's vision is to embed sustainability into the mainstream capital markets, and our core values reflect a commitment to responsible citizenship. Five percent of the profitability of the firm is allocated to the Generation Foundation, which will support global non-profit sustainability initiatives.

Details Hidden

VIM is an active, value-driven, long-term manager which employs a number of methods, including themes, to help identify industries and companies that are well positioned to benefit from medium-term growth regardless of their location, aiming to generate excellent total real returns with minimal risk of permanent capital loss. The firm performs bottom-up analysis on investment opportunities, to derive detailed absolute valuations and where applicable, an assessment of the level and sustainability of dividend yield. Capital preservation and growth are considered paramount in the investment process and encompasses a global approach so as not to artificially constrain their investment universe. VIM has a two phase real return approach. They first seek to select good quality companies for entry into their \"universe of investable companies\". They then typically construct a concentrated portfolio from stocks in the universe by remaining patient in order to pay the right price. The investment process is the same for all global strategies and only differs at the portfolio construction stage. The Global Focus strategy is the most unconstrained. The Global Equity Income strategy aims to pay a high sustainable dividend and is more constrained in the stocks that can be bought. The Global Real Return strategy seeks to further protect the downside by the use of index derivatives.

Recent Transactions
Details Hidden

Baxter International, Inc. purchases Sanofi /Seprafilm Brand from Sanofi

Details Hidden

Baxter International, Inc. purchases Cheetah Medical, Inc. from MVM Partners LLP, Ascension Ventures LLC, Fletcher Spaght Venture Partners LLC, Eastward Capital Partners LLC, Robert Bosch Venture Capital GmbH, HighCape Partners Management LLC

Details Hidden

Baxter International, Inc. purchases True Process, Inc.

Insider Transactions
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onBaxter International, Inc. issued USD Common Stock

Legal Advisor

Advised onBaxter International, Inc. purchases Prism Pharmaceuticals, Inc. from Paul Capital Partners LP, Essex Woodlands Management, Inc.

Underwriter

Advised onBaxter International, Inc. issued USD Common Stock

Legal Advisor

Advised onBaxter International, Inc. purchases Prism Pharmaceuticals, Inc. from Paul Capital Partners LP, Essex Woodlands Management, Inc.

Legal Advisor

Advised onBaxter International, Inc. purchases SuppreMol GmbH from Bayern Kapital GmbH, MIG Verwaltungs AG, ATS Beteiligungsverwaltung GmbH, Zetacube Srl, BioMedPartners AG

Legal Advisor

Advised onCHF Solutions, Inc. purchases Baxter International, Inc. /Aquadex Business from Baxter International, Inc.

Advisors & Consultants
Legal Advisor

Partner at Foley Hoag LLP

Advisor

President at ICNet Systems, Inc.

Advisor

Managing Director at RBC Capital Markets LLC

Clients

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Covetrus, Inc. engages in developing technologies and services for animal health industry. It also provides products, software, and services to help drive improved patient health, strong client relationships, and successful financial outcomes for veterinary professionals. The company was founded by Benjamin J. Shaw in 2014 and is headquartered in Portland, ME.

DaVita is a leading provider of kidney care in the United States, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of September 30, 2012, DaVita operated or provided administrative services at 1,912 outpatient dialysis centers in 43 states in the United States, serving approximately 150,000 patients, and at 24 centers in five countries outside of the United States that serve approximately 1,000 patients.

Key Stats and Financials As of 2019
Market Capitalization
$38.7B
Total Enterprise Value
$46.1B
Earnings Per Share
$1.93
Revenue
$11.4B
Net Profit
$1B
EBITDAMargin
23.74%
Enterprise Value / Sales
4.05x
Enterprise Value EBITDAOperating
16.85x
Debt TEV
0.13x
TEVNet Income
46.01x
Total Debt
$5.96B
EBITDA
$2.7B
Total Equity
$7.91B
Three Year Compounded Annual Growth Rate Of Revenue
3.79%
Five Year Compounded Annual Growth Rate Of Revenue
-7.38%
Non-Profit Donations & Grants
$20K - $50K
2019
$25K - $50K
2019
Investments
Details Hidden

Sigma International General Medical Apparatus LLC manufactures drug-error prevention intravenous infusion pumps. It offers Sigma Spectrum for drug error prevention, Single-Doser for small volume medications and accessories. The company was founded in 1982 by Roger L. Hungerford and is headquartered in Medina, NY.

Details Hidden

Ayogo Health, Inc. provides online networking services to healthcare. It develops games and applications for management of chronic health conditions and patient adherence. The firm offers Empower, a digital tool for healthcare systems that uses behavior change to help healthcare consumers with chronic conditions. The company was founded by Michael Fergusson and Paul Prescod in 2011 and is headquartered in Vancouver, Canada.

Details Hidden

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Suppliers
SciClone Pharmaceuticals Inc. Biotechnology | Foster City, California

SciClone Pharmaceuticals is a US-based, China-focused specialty pharmaceutical company with a product portfolio of therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders. SciClone’s ZADAXIN® (thymalfasin) is approved in over 30 countries and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as a vaccine adjuvant, according to the local regulatory approvals. Besides ZADAXIN, SciClone markets about 14 mostly partnered products in China, including Depakine®, the most widely prescribed broad-spectrum anti-convulsant in China; Tritace®, an ACE inhibitor for the treatment of hypertension; Stilnox®, a fast-acting hypnotic for the short-term treatment of insomnia (marketed as Ambien® in the US); and Aggrastat®, a recently-launched interventional cardiology product. SciClone is also pursuing the registration of several other therapeutic products in China. SciClone is headquartered in Foster City, California.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Semcon AB Commercial Scientific Research | Gothenburg, Sweden

Semcon AB engages in the provision of product development services and product information. It operates through the Engineering Services and Product Information segments. The Engineering Services segment offers services that focus on the energy, automotive, telecom, and life science sectors. The Product Information segment involves in complete information solutions particularly the aftermarket business. The company was founded in 1980 and is headquartered in Goteborg, Sweden.

Awards & Honors
Rank #286
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #286
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Baxter International, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Baxter International, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Baxter International, Inc..